Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Anchoring-and-Adjustment Heuristic01:25

The Anchoring-and-Adjustment Heuristic

7.7K
In order to make good decisions, we use our knowledge and our reasoning. Often, this knowledge and reasoning is sound and solid. However, sometimes, we are swayed by biases or by others manipulating a situation. For example, let’s say you and three friends wanted to rent a house and had a combined target budget of $1,600. The realtor shows you only very run-down houses for $1,600 and then shows you a very nice house for $2,000. Might you ask each person to pay more in rent to get the...
7.7K
Decision Making: P-value Method01:09

Decision Making: P-value Method

6.8K
The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim  is also stated. These statements can act as null and alternative hypotheses:  a null hypothesis would be a neutral statement while the alternative hypothesis can...
6.8K
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation01:24

One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation

1.1K
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
1.1K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

240
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
240
Per-Unit Sequence Models01:26

Per-Unit Sequence Models

428
An ideal Y-Y transformer, grounded through neutral impedances, displays per-unit sequence networks akin to those of a single-phase ideal transformer when subjected to balanced positive- or negative-sequence currents. These currents do not produce neutral currents, and their associated voltage drops.
Zero-sequence currents, which are identical in magnitude and phase, generate a neutral current, resulting in voltage drops across the neutral impedance and the low-voltage winding. If the...
428
Weighted Mean00:57

Weighted Mean

6.2K
While taking the arithmetic, geometric, or harmonic mean of a sample data set, equal importance is assigned to all the data points. However, all the values may not always be equally important in some data sets. An intrinsic bias might make it more important to give more weightage to specific values over others.
For example, consider the number of goals scored in the matches of a tournament. While computing the average number of goals scored in the tournament, it may be more important to...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same author

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.

The Journal of antimicrobial chemotherapy·2026
Same author

An evaluation of designs for Phase I/IIa dose-finding studies in Tuberculosis.

Statistical methods in medical research·2026
Same author

On the Interplay Between Prior Weight and Variance of the Robustification Component in Robust Mixture Prior Bayesian Dynamic Borrowing Approach.

Statistics in medicine·2026
Same author

Computationally Efficient Approach to Operational Prior Specification in Phase I Clinical Trials.

Statistics in medicine·2026
Same author

Modern Clinical Trials: Seamless Designs and Master Protocols.

Cancer medicine·2026
Same journal

Towards optimal environmental policies: policy learning under arbitrary bipartite network interference.

Biostatistics (Oxford, England)·2026
Same journal

Multilevel functional quantile principal component analysis.

Biostatistics (Oxford, England)·2026
Same journal

Adaptive transfer learning for time-to-event modeling with applications in disease risk assessment.

Biostatistics (Oxford, England)·2026
Same journal

High-dimensional test for one-sided hypotheses.

Biostatistics (Oxford, England)·2026
Same journal

NBSR: a Negative Binomial Softmax Regression model for microRNA-seq data analysis.

Biostatistics (Oxford, England)·2026
Same journal

Addressing the influence of unmeasured confounding in observational studies with time-to-event outcomes: a semiparametric sensitivity analysis approach.

Biostatistics (Oxford, England)·2026
See all related articles

Related Experiment Video

Updated: Jan 14, 2026

A Psychophysics Paradigm for the Collection and Analysis of Similarity Judgments
08:12

A Psychophysics Paradigm for the Collection and Analysis of Similarity Judgments

Published on: March 1, 2022

2.9K

Bayesian model averaging for partial ordering continual reassessment methods.

Luka Kovačević1, Weishi Chen1, Helen Barnett2

  • 1MRC Biostatistics Unit, East Forvie Building, Forvie Site, Robinson Way, Cambridge Biomedical Campus, Cambridge CB2 0SR, United Kingdom.

Biostatistics (Oxford, England)
|October 21, 2025
PubMed
Summary
This summary is machine-generated.

The Bayesian model averaged POCRM (BMA-POCRM) enhances drug combination trials by addressing estimation incoherency in dose-finding. This new method improves patient safety and clinician trust by providing more accurate toxicity estimates.

Keywords:
Bayesian inferenceadaptive designincoherencemaximum tolerable dose

More Related Videos

Measuring Attention and Visual Processing Speed by Model-based Analysis of Temporal-order Judgments
13:00

Measuring Attention and Visual Processing Speed by Model-based Analysis of Temporal-order Judgments

Published on: January 23, 2017

10.3K
Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

16.0K

Related Experiment Videos

Last Updated: Jan 14, 2026

A Psychophysics Paradigm for the Collection and Analysis of Similarity Judgments
08:12

A Psychophysics Paradigm for the Collection and Analysis of Similarity Judgments

Published on: March 1, 2022

2.9K
Measuring Attention and Visual Processing Speed by Model-based Analysis of Temporal-order Judgments
13:00

Measuring Attention and Visual Processing Speed by Model-based Analysis of Temporal-order Judgments

Published on: January 23, 2017

10.3K
Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

16.0K

Area of Science:

  • Clinical Pharmacology
  • Biostatistics
  • Drug Development

Background:

  • Phase I clinical trials are critical for advancing new therapies.
  • Traditional dose-finding methods like the 3+3 and Continual Reassessment Method (CRM) struggle with uncertainty in combination drug trials.
  • Combination trials involve simultaneous dose escalation across multiple drugs, creating complex dose-toxicity relationships.

Purpose of the Study:

  • To address the 'estimation incoherency' issue in the CRM for partial ordering (POCRM) for combination drug trials.
  • To introduce and formalize the Bayesian model averaged POCRM (BMA-POCRM) as a solution.
  • To provide theoretical guarantees and demonstrate the effectiveness of BMA-POCRM.

Main Methods:

  • The study analyzes the vulnerability of POCRM to estimation incoherency.
  • Bayesian model averaging is employed to develop BMA-POCRM, considering all possible dose-toxicity orderings simultaneously.
  • Theoretical guarantees for the estimation coherency of both POCRM and BMA-POCRM are derived.

Main Results:

  • POCRM was found to be susceptible to illogical shifts in toxicity estimates, compromising patient safety.
  • BMA-POCRM significantly reduces the frequency of estimation incoherencies by averaging over all possible orderings.
  • Simulation studies and a specific case of POCRM incoherency demonstrate BMA-POCRM's improved performance.

Conclusions:

  • BMA-POCRM offers a more robust and safer approach to dose-finding in Phase I combination drug trials.
  • The method enhances accuracy and reliability compared to the standard POCRM.
  • BMA-POCRM increases clinician trust in dose-finding models within complex trial settings.